ClinicalTrials.Veeva

Menu

Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Impotence

Treatments

Drug: Cialis (Tadalafil)
Drug: UK0369,003

Study type

Interventional

Funder types

Industry

Identifiers

NCT00174486
A3711030

Details and patient eligibility

About

Assessment of duration of action, safety & toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks.

Sex

Male

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Erectile Dysfunction

Exclusion criteria

  • Alpha blockers and Nitrates of any preparation

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems